With another $148M in the bank, Gyroscope Therapeutics looks to hustle its AMD gene therapy through mid-stage tests
A month and a half later, Gyroscope Therapeutics’ Phase I/II win for its dry-AMD gene therapy is already paying off. On Friday, the biotech took the wraps off a $148 million Series C round to advance the candidate through two Phase II trials in patients with a debilitating eye disorder that causes gradual and permanent blindness.
Syncona — which founded Gyroscope with Cambridge Enterprise — contributed $42.3 million to the Series C round, and now maintains a 54% stake in the London-based biotech.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.